Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin and cytarabine with or without PSC-833 in elderly patients with untreated acute myeloid leukemia
NL-OMON25298Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 1997
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Daunorubicin + cytarabine with Daunorubicin + cytarabine + PSC-833 (2 arms). Primary endpoint: Event-free survival. Started May 1997; status: active, not recruiting.
02
Drugs
valspodardaunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON25298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25298.